Sector: Health Care
Director information for ARROWHEAD PHARMACEUTICALS INC (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Adeoye Olukotun, MD, MPH | Independent Director | 80 | ["Mayo Clinic trained cardiologist", "Chief Executive Officer of CR Strategies, LLC since 2001", "Former board member of Tonix Pharmaceuticals Holding Corp.", "Former CEO of Epigen Pharmaceuticals, Inc. from 2014 to 2017", "Former Vice Board Chair of CardioVax, Inc. from 2012 to 2016", "Over 35 years of experience in the pharmaceutical industry", "Experience at Pfizer, Bristol-Myers Squibb, and Mallinckrodt", "Received Medical Doctor degree from Albert Einstein College of Medicine", "Masters in Public Health from Harvard University School of Public Health"] | ["Science Committee (Co-Chair)", "Nomination Committee"] | 2025 |
| Christopher Anzalone, PhD | Chief Executive Officer, President, Director & Board Chair | 55 | ["Deep understanding of the business through his role as Chief Executive Officer", "Extensive experience in business development", "Biotechnology", "Drug development", "Company-building", "Venture capital"] | [] | 2025 |
| Douglas Ingram | Independent Director | 62 | ["President and Chief Executive Officer of Sarepta Therapeutics, Inc.", "Chief Executive Officer, President and Director of Chase Pharmaceuticals Corporation", "President of Allergan, Inc.", "President, Europe, Africa and Middle East at Allergan", "Executive Vice President, Chief Administrative Officer, and Secretary at Allergan", "General Counsel of Allergan", "Special advisor to the Chief Executive Officer of Actavis", "Director of Pacific Mutual Holding Company"] | [] | 2025 |
| Hongbo Lu | Independent Director | 54 | ["Founding member of NEXTBio Capital", "Over 20 years of healthcare investment management experience", "Former Managing Partner at Vivo Capital LLC", "Former Managing Partner at Lilly Asia Ventures", "Former Managing Director at OrbiMed Advisors", "Served on the boards of over 20 healthcare companies", "Earned a Ph.D. in Bioengineering", "M.B.A. from the Haas School of Business", "Graduated with honors from Tsinghua University"] | ["Science Committee", "Nomination Committee", "Compensation Committee"] | 2025 |
| Mauro Ferrari, PhD | Independent Director | 65 | ["Affiliate Professor of Pharmaceutics at the University of Washington", "President, CEO, and Board Member of BrYet US, Inc.", "Chairman of the Board of BrYet Europe", "Former President and CEO of The Houston Methodist Hospital Research Institute", "Executive Vice President of Houston Methodist Hospital", "Senior Associate Dean of Weill Cornell Medical College", "Expert in cancer therapeutics, nanomedicine, and biomedical nanotechnology", "Tenured professorships at UC Berkeley, The Ohio State University, and The University of Texas Health Science Center", "Previous roles at MD Anderson Cancer Center and Rice University", "Special Expert on Nanotechnology at The National Cancer Institute", "Over 500 published articles and over 30 issued patents"] | ["Science Committee (Co-Chair)", "Audit Committee", "Nomination Committee"] | 2025 |
| Michael S. Perry, DVM, PhD | Independent Director | 65 | ["Venture Partner with Bioscience Managers", "Chairman and board member of 7 Hills Pharma", "CEO of Avita Medical, Inc.", "Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit", "Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp", "SVP and Global Head of R&D at Baxter Healthcare", "President and CEO of Cell & Gene Therapy at Novartis AG", "VP Regulatory Affairs at Novartis, Sandoz Pharmaceuticals, and Syntex Corporation", "Director of Regulatory Affairs at Schering-Plough Corporation", "Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus", "Faculty at Houston Methodist", "Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute", "Holds an Honors Bachelor of Science in Physics and Engineering", "PhD in Biomedical Pharmacology from the University of Guelph", "Doctor of Veterinary Medicine & Surgery from Ontario Veterinary College", "Graduate of the International Advanced Management Program at Harvard Business School"] | ["Compensation Committee (Chair)", "Nomination Committee", "Science Committee"] | 2025 |
| Victoria Vakiener | Independent Director | 61 | ["Current board member of Chimerix", "Former Chief Commercial Officer of Epizyme, Inc.", "Over twenty years at Johnson & Johnson in leadership positions", "Experience at Schering-Plough in scientific and commercial roles", "BS in Biochemistry from Albright College"] | ["Nomination Committee (Chair)", "Audit Committee"] | 2025 |
| William Waddill | Lead Independent Director | 67 | ["Over 35 years in commercial banking and public accounting", "Over 30 years in biotechnology industry", "Former Senior Vice President and CFO of Calithera Bioscience", "Former Senior Vice President and CFO at OncoMed Pharmaceuticals", "Founder and principal at Square One Finance", "BS in accounting from the University of Illinois, Chicago", "Certification as a public accountant (inactive)"] | ["Audit Committee (Chair)", "Compensation Committee", "Nomination Committee"] | 2025 |
